This article contains content that is written like an advertisement .(July 2023) |
Fox Chase Cancer Center | |
---|---|
Temple University Health System | |
Geography | |
Location | 333 Cottman Avenue, Philadelphia, Pennsylvania, United States |
Coordinates | 40°04′19″N75°05′25″W / 40.071848°N 75.090206°W |
Organization | |
Funding | Non-profit hospital |
Type | Specialist |
Affiliated university | Temple University School of Medicine, Temple University |
Services | |
Standards | NCI-designated Comprehensive Cancer Center |
Speciality | Oncology, Teaching hospital, Cancer research |
History | |
Former name(s) | American Oncologic Hospital, Institute for Cancer Research |
Opened | 1904[1] (as the American Oncologic Hospital) |
Links | |
Website | www |
Fox Chase Cancer Center is a National Cancer Institute-designated Comprehensive Cancer Center research facility and hospital located in the Fox Chase section of Philadelphia, Pennsylvania, United States. The main facilities of the center are located on property adjoining Burholme Park. The center is part of the Temple University Health System (TUHS) and specializes in the treatment and prevention of cancer.
The center was formed in 1974 by the merger of the American Oncologic Hospital, which was founded in 1904 as the first cancer hospital in the United States, [2] and the Institute for Cancer Research, founded in 1927.
In 1967 a large wing of the hospital was constructed based on a design by Vincent G. Kling using steep slopes of poured concrete and roof tiles by Ludowici. [3]
In 1995, Fox Chase also became a founding member of the National Comprehensive Cancer Network, an alliance of 21 of the nation's leading academic cancer centers.
The center was an independent, non-profit institution until it became part of TUHS July 1, 2012. On December 15, 2011, Fox Chase Cancer Center and Temple University Health system signed an affiliation agreement. [4] Under the agreement, Fox Chase has connected and extended its current operations into the adjoining 176-bed and 33-acre Jeanes Hospital, which is already a part of the Temple University Health System. Fox Chase is considered the "Cancer Hub" of the Temple University Health System.
The hospital has almost 2,400 employees and an operating budget of $300 million. Annual hospital admissions average about 4,100 and outpatient visits to physicians exceed 69,000 a year. As of 2014, the Fox Chase Cancer Center was ranked as the 19th best cancer hospital in the United States by U.S. News & World Report . [5]
Fox Chase became the first US cancer center and the first hospital in Pennsylvania to earn the American Nurses Association Magnet Award for Nursing Excellence in 2000. Fox Chase has continued to win this designation for a total of six awards, one of only 15 hospitals in the United States to do so. [6] In 2020, Fox Chase Cancer Center received the Press Ganey's Guardian of Excellence Award for excellence in clinical care in outpatient services. [7]
Baruch Samuel Blumberg, known as Barry Blumberg, was an American physician, geneticist, and co-recipient of the 1976 Nobel Prize in Physiology or Medicine, for his work on the hepatitis B virus while an investigator at the NIH and at the Fox Chase Cancer Center. He was president of the American Philosophical Society from 2005 until his death.
Recombinant DNA (rDNA) molecules are DNA molecules formed by laboratory methods of genetic recombination that bring together genetic material from multiple sources, creating sequences that would not otherwise be found in the genome.
An oncovirus or oncogenic virus is a virus that can cause cancer. This term originated from studies of acutely transforming retroviruses in the 1950–60s, when the term "oncornaviruses" was used to denote their RNA virus origin. With the letters "RNA" removed, it now refers to any virus with a DNA or RNA genome causing cancer and is synonymous with "tumor virus" or "cancer virus". The vast majority of human and animal viruses do not cause cancer, probably because of longstanding co-evolution between the virus and its host. Oncoviruses have been important not only in epidemiology, but also in investigations of cell cycle control mechanisms such as the retinoblastoma protein.
Maurice Ralph Hilleman was a leading American microbiologist who specialized in vaccinology and developed over 40 vaccines, an unparalleled record of productivity. According to one estimate, his vaccines save nearly eight million lives each year. He has been described as one of the most influential vaccinologists ever. He has been called the "father of modern vaccines". Robert Gallo called Hilleman "the most successful vaccinologist in history". He has been noted by some researchers as having saved more lives than any other scientist in the 20th century.
Alfred George Knudson, Jr. was an American physician and geneticist specializing in cancer genetics. Among his many contributions to the field was the formulation of the Knudson hypothesis in 1971, which explains the effects of mutation on carcinogenesis.
Rudolf Jaenisch is a Professor of Biology at MIT and a founding member of the Whitehead Institute for Biomedical Research. He is a pioneer of transgenic science, in which an animal’s genetic makeup is altered. Jaenisch has focused on creating genetically modified mice to study cancer, epigenetic reprogramming and neurological diseases.
Harvey James Alter is an American medical researcher, virologist, physician and Nobel Prize laureate, who is best known for his work that led to the discovery of the hepatitis C virus. Alter is the former chief of the infectious disease section and the associate director for research of the Department of Transfusion Medicine at the Warren Grant Magnuson Clinical Center in the National Institutes of Health (NIH) in Bethesda, Maryland. In the mid-1970s, Alter and his research team demonstrated that most post-transfusion hepatitis cases were not due to hepatitis A or hepatitis B viruses. Working independently, Alter and Edward Tabor, a scientist at the U.S. Food and Drug Administration, proved through transmission studies in chimpanzees that a new form of hepatitis, initially called "non-A, non-B hepatitis" caused the infections, and that the causative agent was probably a virus. This work eventually led to the discovery of the hepatitis C virus in 1988, for which he shared the Nobel Prize in Physiology or Medicine in 2020 along with Michael Houghton and Charles M. Rice.
HBsAg is the surface antigen of the hepatitis B virus (HBV). Its presence in blood indicates existing hepatitis B infection.
Lankenau Institute for Medical Research (LIMR), founded in 1927, is a nonprofit, biomedical research institute located on the campus of Lankenau Medical Center in Wynnewood, Pennsylvania, serving as the research division of the Main Line Health System in suburban Philadelphia. LIMR focuses on studies of cancer, cardiovascular, autoimmune, gastrointestinal and other diseases. It houses a center for population health research.
Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people, routine immunization results in more than 95% of people being protected.
Hepatitis B is an infectious disease caused by the Hepatitis B virus (HBV) that affects the liver; it is a type of viral hepatitis. It can cause both acute and chronic infection.
Harald zur Hausen NAS EASA APS was a German virologist. He carried out research on cervical cancer and discovered the role of papilloma viruses in cervical cancer, for which he received the Nobel Prize in Physiology or Medicine in 2008. He was chairman of the German Cancer Research Center in Heidelberg.
A genetically modified mouse or genetically engineered mouse model (GEMM) is a mouse that has had its genome altered through the use of genetic engineering techniques. Genetically modified mice are commonly used for research or as animal models of human diseases and are also used for research on genes. Together with patient-derived xenografts (PDXs), GEMMs are the most common in vivo models in cancer research. Both approaches are considered complementary and may be used to recapitulate different aspects of disease. GEMMs are also of great interest for drug development, as they facilitate target validation and the study of response, resistance, toxicity and pharmacodynamics.
Beatrice Mintz was an American embryologist who contributed to the understanding of genetic modification, cellular differentiation, and cancer, particularly melanoma. Mintz was a pioneer of genetic engineering techniques and was among the first scientists to generate both chimeric and transgenic mammals.
Sir Bruce Anthony John Ponder FMedSci FAACR FRS FRCP is an English geneticist and cancer researcher. He is Emeritus Professor of Oncology at the University of Cambridge and former director of the Cancer Research UK Cambridge Institute and of the Cancer Research UK Cambridge Cancer Centre.
Dr. Manfred E. Bayer was a medical doctor and a microscopist, best known for his research in bacterial and viral infrastructure using electron microscopy. He was the first person to visualize yellow fever virus in cultured cells and to obtain ultra-thin sections of the cell wall of E. coli by penicillin.
Robert Palmer Beasley was an American physician, public health educator and epidemiologist whose work on hepatitis B involved extensive investigations in Taiwan. That work established that hepatitis B virus (HBV) is a primary cause of liver cancer and that hepatitis B virus is transmitted from mother to infant during childbirth. Beasley and his colleagues also proved that HBV mother-to-infant transmission is preventable by at-birth vaccination. Due to this work, the World Health Assembly designated HBV as the seventh global vaccine in 1992. He later became the author of HBV immunization policies for the World Health Organization.
Peter Carey Nowell was a cancer researcher and co-discoverer of the Philadelphia chromosome. At the time of his death, he was the Gaylord P. and Mary Louise Harnwell Emeritus Professor of Pathology and Laboratory Medicine at the University of Pennsylvania.
The Hepatitis B Foundation (HBF) is an American nonprofit organization dedicated to finding a cure for hepatitis B and improving the lives of those already affected by the disease. Established in 1991, the foundation's headquarters is in Doylestown, PA. It is the only non-profit in the United States focused solely on hepatitis B. The foundation conducts biomedical research, promotes disease awareness, and acts as an information source for patients, the medical community, and the general public. The Hepatitis B Foundation's research arm, the Baruch S. Blumberg Institute, has the largest number of non-profit scientists dedicated to hepatitis B research in the world. The organization also leads national public policy initiatives and international public health programs.
The woolly monkey hepatitis B virus (WMHBV) is a viral species of the Orthohepadnavirus genus of the Hepadnaviridae family. Its natural host is the woolly monkey (Lagothrix), an inhabitant of South America categorized as a New World primate. WMHBV, like other hepatitis viruses, infects the hepatocytes, or liver cells, of its host organism. It can cause hepatitis, liver necrosis, cirrhosis, and hepatocellular carcinoma. Because nearly all species of Lagothrix are threatened or endangered, researching and developing a vaccine and/or treatment for WMHBV is important for the protection of the whole woolly monkey genus.
{{cite journal}}
: CS1 maint: multiple names: authors list (link){{cite journal}}
: CS1 maint: multiple names: authors list (link){{cite web}}
: CS1 maint: multiple names: authors list (link){{cite journal}}
: CS1 maint: multiple names: authors list (link)